SomaLogic, Inc. announced that preliminary, unaudited revenue for the full year 2022 is expected to be at the high end of its guidance range of $93 to $98 million, reflecting approximately 20% year-over-year revenue growth.
Standard BioTools Inc.
Equities
SLGC
US83444K1051
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+24.76% | 46.56B | |
+45.38% | 41.67B | |
+0.27% | 41.16B | |
+33.07% | 32.4B | |
+21.10% | 28.18B | |
-6.35% | 28.1B | |
+48.94% | 14.52B | |
+47.49% | 13.74B | |
+3.04% | 12.17B |